Cyclacel Pharmaceuticals (NASDAQ:CYCC) Receives New Coverage from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Cyclacel Pharmaceuticals (NASDAQ:CYCC) in a research report released on Monday. The brokerage issued a sell rating on the biotechnology company’s stock.

Cyclacel Pharmaceuticals Stock Up 2.0 %

Shares of NASDAQ CYCC opened at $1.01 on Monday. The stock’s 50-day simple moving average is $1.07 and its two-hundred day simple moving average is $1.60. Cyclacel Pharmaceuticals has a twelve month low of $0.75 and a twelve month high of $11.34. The firm has a market capitalization of $2.17 million, a P/E ratio of -0.06 and a beta of 0.51.

Cyclacel Pharmaceuticals (NASDAQ:CYCC) last posted its quarterly earnings data on Wednesday, August 14th. The biotechnology company reported ($0.72) earnings per share for the quarter, topping the consensus estimate of ($0.83) by $0.11. Cyclacel Pharmaceuticals had a negative net margin of 21,963.75% and a negative return on equity of 1,901.11%. During the same period in the previous year, the business earned ($6.60) EPS. As a group, research analysts anticipate that Cyclacel Pharmaceuticals will post -2.29 EPS for the current fiscal year.

Institutional Investors Weigh In On Cyclacel Pharmaceuticals

An institutional investor recently bought a new position in Cyclacel Pharmaceuticals stock. Armistice Capital LLC acquired a new stake in Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) in the second quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 134,000 shares of the biotechnology company’s stock, valued at approximately $217,000. Armistice Capital LLC owned approximately 9.18% of Cyclacel Pharmaceuticals as of its most recent filing with the SEC. Institutional investors own 23.58% of the company’s stock.

About Cyclacel Pharmaceuticals

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.